{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T00:55:48Z","timestamp":1792803348982,"version":"4.5.0"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2024,3,5]],"date-time":"2024-03-05T00:00:00Z","timestamp":1709596800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,3,5]],"date-time":"2024-03-05T00:00:00Z","timestamp":1709596800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Rheumatol"],"published-print":{"date-parts":[[2024,5]]},"DOI":"10.1007\/s10067-024-06928-1","type":"journal-article","created":{"date-parts":[[2024,3,5]],"date-time":"2024-03-05T15:01:41Z","timestamp":1709650901000},"page":"1723-1733","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Anti-tumor necrosis factor (aTNF) weaning strategy in juvenile idiopathic arthritis (JIA): does duration matter?"],"prefix":"10.1007","volume":"43","author":[{"given":"Kai Liang","family":"Teh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lena","family":"Das","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yun Xin","family":"Book","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sook Fun","family":"Hoh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaocong","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1387-1169","authenticated-orcid":false,"given":"Thaschawee","family":"Arkachaisri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,3,5]]},"reference":[{"issue":"9563","key":"6928_CR1","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1016\/S0140-6736(07)60363-8","volume":"369","author":"A Ravelli","year":"2007","unstructured":"Ravelli A, Martini A (2007) Juvenile idiopathic arthritis. Lancet 369(9563):767\u2013778","journal-title":"Lancet"},{"issue":"1","key":"6928_CR2","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12969-020-00443-8","volume":"18","author":"M Dave","year":"2020","unstructured":"Dave M, Rankin J, Pearce M et al (2020) Global prevalence estimates of three chronic musculoskeletal conditions: club foot, juvenile idiopathic arthritis and juvenile systemic lupus erythematosus. Pediatr Rheumatol 18(1):1\u20137","journal-title":"Pediatr Rheumatol"},{"issue":"2","key":"6928_CR3","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1080\/03009742.2018.1493140","volume":"48","author":"K Rebane","year":"2019","unstructured":"Rebane K, Ristolainen L, Relas H et al (2019) Disability and health-related quality of life are associated with restricted social participation in young adults with juvenile idiopathic arthritis. Scand J Rheumatol 48(2):105\u2013113","journal-title":"Scand J Rheumatol"},{"issue":"12","key":"6928_CR4","doi-asserted-by":"publisher","first-page":"3727","DOI":"10.1093\/rheumatology\/keaa118","volume":"59","author":"A Chhabra","year":"2020","unstructured":"Chhabra A, Robinson C, Houghton K et al (2020) Long-term outcomes and disease course of children with juvenile idiopathic arthritis in the ReACCh-Out cohort: a two-centre experience. Rheumatology 59(12):3727\u20133730","journal-title":"Rheumatology"},{"issue":"1","key":"6928_CR5","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1038\/s41572-021-00332-8","volume":"8","author":"A Martini","year":"2022","unstructured":"Martini A, Lovell DJ, Albani S et al (2022) Juvenile idiopathic arthritis. Nat Rev Dis Primers 8(1):5","journal-title":"Nat Rev Dis Primers"},{"key":"6928_CR6","doi-asserted-by":"publisher","first-page":"2339","DOI":"10.1007\/s10067-020-05520-7","volume":"40","author":"KL Teh","year":"2021","unstructured":"Teh KL, Tanya M, Das L et al (2021) Outcomes and predictors of juvenile idiopathic arthritis in Southeast Asia: a Singapore longitudinal study over a decade. Clin Rheumatol 40:2339\u20132349","journal-title":"Clin Rheumatol"},{"issue":"1","key":"6928_CR7","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12969-021-00629-8","volume":"19","author":"LN Zaripova","year":"2021","unstructured":"Zaripova LN, Midgley A, Christmas SE et al (2021) Juvenile idiopathic arthritis: from aetiopathogenesis to therapeutic approaches. Pediatr Rheumatol 19(1):1\u201314","journal-title":"Pediatr Rheumatol"},{"key":"6928_CR8","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1038\/s41584-024-01079-8","volume":"20","author":"S Shenoi","year":"2024","unstructured":"Shenoi S, Horneff G, Aggarwal A et al (2024) Treatment of non-systemic juvenile idiopathic arthritis. Nat Rev Rheumatol 20:170\u2013181","journal-title":"Nat Rev Rheumatol"},{"issue":"4","key":"6928_CR9","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1002\/art.42037","volume":"74","author":"KB Onel","year":"2022","unstructured":"Onel KB, Horton DB, Lovell DJ et al (2022) 2021 American College of Rheumatology guideline for the treatment of juvenile idiopathic arthritis: therapeutic approaches for oligoarthritis, temporomandibular joint arthritis, and systemic juvenile idiopathic arthritis. Arthritis Rheumatol 74(4):553\u2013569","journal-title":"Arthritis Rheumatol"},{"issue":"6","key":"6928_CR10","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1002\/acr.23870","volume":"71","author":"S Ringold","year":"2019","unstructured":"Ringold S, Angeles-Han ST, Beukelman T et al (2019) 2019 American College of Rheumatology\/Arthritis Foundation guideline for the treatment of juvenile idiopathic arthritis: therapeutic approaches for non-systemic polyarthritis, sacroiliitis, and enthesitis. Arthritis Care Res 71(6):717\u2013734","journal-title":"Arthritis Care Res"},{"issue":"9","key":"6928_CR11","doi-asserted-by":"publisher","first-page":"2794","DOI":"10.1002\/art.24777","volume":"60","author":"E Giannini","year":"2009","unstructured":"Giannini E, Ilowite N, Lovell D et al (2009) Long-term safety and effectiveness of etanercept in children with selected categories of juvenile idiopathic arthritis. Arthritis Rheum 60(9):2794\u20132804","journal-title":"Arthritis Rheum"},{"issue":"10","key":"6928_CR12","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1038\/nrrheum.2010.142","volume":"6","author":"PJ Hashkes","year":"2010","unstructured":"Hashkes PJ, Uziel Y, Laxer RM (2010) The safety profile of biologic therapies for juvenile idiopathic arthritis. Nat Rev Rheumatol 6(10):561\u2013571","journal-title":"Nat Rev Rheumatol"},{"key":"6928_CR13","doi-asserted-by":"publisher","first-page":"1303","DOI":"10.1007\/s40744-021-00331-x","volume":"8","author":"LR Grazziotin","year":"2021","unstructured":"Grazziotin LR, Currie G, Twilt M et al (2021) Evaluation of real-world healthcare resource utilization and associated costs in children with juvenile idiopathic arthritis: a Canadian retrospective cohort study. Rheumatol Ther 8:1303\u20131322","journal-title":"Rheumatol Ther"},{"issue":"1","key":"6928_CR14","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12969-016-0083-7","volume":"14","author":"P Livermore","year":"2016","unstructured":"Livermore P, Eleftheriou D, Wedderburn L (2016) The lived experience of juvenile idiopathic arthritis in young people receiving etanercept. Pediatr Rheumatol 14(1):1\u20136","journal-title":"Pediatr Rheumatol"},{"issue":"1","key":"6928_CR15","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12969-022-00769-5","volume":"20","author":"J Gieling","year":"2022","unstructured":"Gieling J, van den Bemt B, Hoppenreijs E et al (2022) Discontinuation of biologic DMARDs in non-systemic JIA patients: a scoping review of relapse rates and associated factors. Pediatr Rheumatol 20(1):1\u201312","journal-title":"Pediatr Rheumatol"},{"issue":"3","key":"6928_CR16","doi-asserted-by":"publisher","first-page":"352","DOI":"10.3899\/jrheum.161078","volume":"44","author":"DB Horton","year":"2017","unstructured":"Horton DB, Onel KB, Beukelman T et al (2017) Attitudes and approaches for withdrawing drugs for children with clinically inactive nonsystemic JIA: a survey of the childhood arthritis and rheumatology research alliance. J Rheumatol 44(3):352\u2013360","journal-title":"J Rheumatol"},{"issue":"2","key":"6928_CR17","first-page":"390","volume":"31","author":"RE Petty","year":"2004","unstructured":"Petty RE, Southwood TR, Manners P et al (2004) International League of Associations for Rheumatology classification of juvenile idiopathic arthritis: second revision, Edmonton, 2001. J Rheumatol 31(2):390\u2013392","journal-title":"J Rheumatol"},{"issue":"11","key":"6928_CR18","doi-asserted-by":"publisher","first-page":"1958","DOI":"10.1136\/annrheumdis-2015-208642","volume":"75","author":"RG Lambert","year":"2016","unstructured":"Lambert RG, Bakker PA, van der Heijde D et al (2016) Defining active sacroiliitis on MRI for classification of axial spondyloarthritis: update by the ASAS MRI working group. Ann Rheum Dis 75(11):1958\u20131963","journal-title":"Ann Rheum Dis"},{"issue":"5","key":"6928_CR19","doi-asserted-by":"publisher","first-page":"518","DOI":"10.3899\/jrheum.180785","volume":"46","author":"P Stoustrup","year":"2019","unstructured":"Stoustrup P, Resnick CM, Pedersen TK et al (2019) Standardizing terminology and assessment for orofacial conditions in juvenile idiopathic arthritis: international, multidisciplinary consensus-based recommendations. J Rheumatol 46(5):518\u2013522","journal-title":"J Rheumatol"},{"issue":"11","key":"6928_CR20","first-page":"2290","volume":"31","author":"CA Wallace","year":"2004","unstructured":"Wallace CA, Ruperto N, Giannini E et al (2004) Preliminary criteria for clinical remission for select categories of juvenile idiopathic arthritis. J Rheumatol 31(11):2290\u20132294","journal-title":"J Rheumatol"},{"issue":"6","key":"6928_CR21","first-page":"819","volume":"77","author":"A Ravelli","year":"2018","unstructured":"Ravelli A, Consolaro A, Horneff G et al (2018) Treating juvenile idiopathic arthritis to target: recommendations of an international task force. Ann Rheum Dis 77(6):819\u2013828","journal-title":"Ann Rheum Dis"},{"issue":"8","key":"6928_CR22","doi-asserted-by":"publisher","first-page":"1428","DOI":"10.1136\/annrheumdis-2016-209201","volume":"75","author":"G Schett","year":"2016","unstructured":"Schett G, Emery P, Tanaka Y et al (2016) Tapering biologic and conventional DMARD therapy in rheumatoid arthritis: current evidence and future directions. Ann Rheum Dis 75(8):1428\u20131437","journal-title":"Ann Rheum Dis"},{"issue":"11","key":"6928_CR23","doi-asserted-by":"publisher","first-page":"1847","DOI":"10.1093\/rheumatology\/kew464","volume":"56","author":"CJ Edwards","year":"2017","unstructured":"Edwards CJ, Fautrel B, Schulze-Koops H et al (2017) Dosing down with biologic therapies: a systematic review and clinicians\u2019 perspective. Rheumatology 56(11):1847\u20131856","journal-title":"Rheumatology"},{"key":"6928_CR24","first-page":"1465","volume":"5","author":"LM Verhoef","year":"2019","unstructured":"Verhoef LM, van den Bemt BJ, van der Maas A et al (2019) Down-titration and discontinuation strategies of tumour necrosis factor\u2013blocking agents for rheumatoid arthritis in patients with low disease activity. Cochrane Database Syst Rev 5:1465\u20131858","journal-title":"Cochrane Database Syst Rev"},{"issue":"7","key":"6928_CR25","doi-asserted-by":"publisher","first-page":"1228","DOI":"10.1136\/ard.2008.101030","volume":"68","author":"F Prince","year":"2009","unstructured":"Prince F, Twilt M, Simon S et al (2009) When and how to stop etanercept after successful treatment of patients with juvenile idiopathic arthritis. Ann Rheum Dis 68(7):1228\u20131229","journal-title":"Ann Rheum Dis"},{"issue":"9","key":"6928_CR26","doi-asserted-by":"publisher","first-page":"1970","DOI":"10.3899\/jrheum.100219","volume":"37","author":"A Remesal","year":"2010","unstructured":"Remesal A, De Inocencio J, Merino R et al (2010) Discontinuation of etanercept after successful treatment in patients with juvenile idiopathic arthritis. J Rheumatol 37(9):1970\u20131971","journal-title":"J Rheumatol"},{"issue":"6","key":"6928_CR27","first-page":"919","volume":"28","author":"P Pratsidou-Gertsi","year":"2010","unstructured":"Pratsidou-Gertsi P, Trachana M, Pardalos G et al (2010) A follow-up study of patients with juvenile idiopathic arthritis who discontinued etanercept due to disease remission. Clin Exp Rheumatol 28(6):919\u201322","journal-title":"Clin Exp Rheumatol"},{"key":"6928_CR28","doi-asserted-by":"publisher","first-page":"2277","DOI":"10.1007\/s00296-012-2642-7","volume":"33","author":"Y Cai","year":"2013","unstructured":"Cai Y, Liu X, Zhang W et al (2013) Clinical trial of etanercept tapering in juvenile idiopathic arthritis during remission. Rheumatol Int 33:2277\u20132282","journal-title":"Rheumatol Int"},{"issue":"7","key":"6928_CR29","doi-asserted-by":"publisher","first-page":"1133","DOI":"10.1007\/s00296-022-05108-1","volume":"42","author":"A Garc\u00eda-Fern\u00e1ndez","year":"2022","unstructured":"Garc\u00eda-Fern\u00e1ndez A, Briones-Figueroa A, Calvo-Sanz L et al (2022) Evaluation of flare rate and reduction strategies for bDMARDs in juvenile idiopathic arthritis: real world data from a single-centre cohort. Rheumatol Int 42(7):1133\u20131142","journal-title":"Rheumatol Int"},{"issue":"2","key":"6928_CR30","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1002\/art.41488","volume":"73","author":"P Quartier","year":"2021","unstructured":"Quartier P, Alexeeva E, Constantin T et al (2021) Tapering canakinumab monotherapy in patients with systemic juvenile idiopathic arthritis in clinical remission: results from a phase IIIb\/IV open-label, randomized study. Arthritis Rheumatol 73(2):336\u2013346","journal-title":"Arthritis Rheumatol"},{"issue":"6","key":"6928_CR31","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1007\/s40272-019-00362-6","volume":"21","author":"O Halyabar","year":"2019","unstructured":"Halyabar O, Mehta J, Ringold S et al (2019) Treatment withdrawal following remission in juvenile idiopathic arthritis: a systematic review of the literature. Pediatr Drugs 21(6):469\u2013492","journal-title":"Pediatr Drugs"},{"issue":"5","key":"6928_CR32","doi-asserted-by":"publisher","first-page":"1926","DOI":"10.1093\/rheumatology\/keac463","volume":"62","author":"L Kearsley-Fleet","year":"2023","unstructured":"Kearsley-Fleet L, Baildam E, Beresford MW et al (2023) Successful stopping of biologic therapy for remission in children and young people with juvenile idiopathic arthritis. Rheumatology 62(5):1926\u20131935","journal-title":"Rheumatology"},{"issue":"7","key":"6928_CR33","doi-asserted-by":"publisher","first-page":"1046","DOI":"10.1002\/acr.23435","volume":"70","author":"G Simonini","year":"2018","unstructured":"Simonini G, Ferrara G, Pontikaki I et al (2018) Flares after withdrawal of biologic therapies in juvenile idiopathic arthritis: clinical and laboratory correlates of remission duration. Arthritis Care Res 70(7):1046\u20131051","journal-title":"Arthritis Care Res"},{"key":"6928_CR34","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/ar4280","volume":"15","author":"K Jiang","year":"2013","unstructured":"Jiang K, Frank MB, Chen Y et al (2013) Genomic characterization of remission in juvenile idiopathic arthritis. Arthritis Res Ther 15:1\u201314","journal-title":"Arthritis Res Ther"},{"key":"6928_CR35","doi-asserted-by":"publisher","first-page":"665170","DOI":"10.3389\/fmed.2021.665170","volume":"8","author":"C-H Liao","year":"2021","unstructured":"Liao C-H, Chiang B-L, Yang Y-H (2021) Tapering of biological agents in juvenile ERA patients in daily clinical practice. Front Med 8:665170","journal-title":"Front Med"},{"issue":"10","key":"6928_CR36","doi-asserted-by":"publisher","first-page":"3027","DOI":"10.1007\/s10067-022-06275-z","volume":"41","author":"KL Teh","year":"2022","unstructured":"Teh KL, Das L, Book YX et al (2022) Sacroiliitis at diagnosis as a protective predictor against disease flare after stopping medication: outcomes of a Southeast Asian enthesitis-related arthritis (ERA) longitudinal cohort. Clin Rheumatol 41(10):3027\u20133034","journal-title":"Clin Rheumatol"},{"issue":"7","key":"6928_CR37","doi-asserted-by":"publisher","first-page":"990","DOI":"10.1136\/annrheumdis-2021-222029","volume":"81","author":"J Gerss","year":"2022","unstructured":"Gerss J, Tedy M, Klein A et al (2022) Prevention of disease flares by risk-adapted stratification of therapy withdrawal in juvenile idiopathic arthritis: results from the PREVENT-JIA trial. Ann Rheum Dis 81(7):990\u2013997","journal-title":"Ann Rheum Dis"},{"issue":"5","key":"6928_CR38","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1097\/BOR.0000000000000948","volume":"35","author":"D Abel","year":"2023","unstructured":"Abel D, Weiss PF (2023) When to stop medication in juvenile idiopathic arthritis. Curr Opin Rheumatol 35(5):265\u2013272","journal-title":"Curr Opin Rheumatol"},{"issue":"2","key":"6928_CR39","first-page":"120","volume":"46","author":"PP Aires","year":"2021","unstructured":"Aires PP, Terreri M, Silva VB et al (2021) Duration of inactive disease while off disease-modifying anti-rheumatic drugs seems to influence flare rates in juvenile idiopathic arthritis: an observational retrospective study. Acta Reumatologica Port 46(2):120\u2013125","journal-title":"Acta Reumatologica Port"},{"issue":"10","key":"6928_CR40","doi-asserted-by":"publisher","first-page":"3163","DOI":"10.1002\/art.30502","volume":"63","author":"K Baszis","year":"2011","unstructured":"Baszis K, Garbutt J, Toib D et al (2011Oct) Clinical outcomes after withdrawal of anti-tumor necrosis factor \u03b1 therapy in patients with juvenile idiopathic arthritis: a twelve-year experience. Arthritis Rheum 63(10):3163\u20133168","journal-title":"Arthritis Rheum"},{"issue":"4","key":"6928_CR41","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1002\/acr.24994","volume":"75","author":"S Ringold","year":"2023","unstructured":"Ringold S, Dennos AC, Kimura Y et al (2023) Disease recapture rates after medication discontinuation and flare in juvenile idiopathic arthritis: an observational study within the childhood arthritis and rheumatology research alliance registry. Arthritis Care Res 75(4):715\u2013723","journal-title":"Arthritis Care Res"},{"issue":"8","key":"6928_CR42","first-page":"1023","volume":"79","author":"P Emery","year":"2020","unstructured":"Emery P, Burmester GR, Naredo E et al (2020) Adalimumab dose tapering in patients with rheumatoid arthritis who are in long-standing clinical remission: results of the phase IV PREDICTRA study. Ann Rheum Dis 79(8):1023\u20131030","journal-title":"Ann Rheum Dis"},{"issue":"10","key":"6928_CR43","doi-asserted-by":"publisher","first-page":"1296","DOI":"10.1136\/ard-2023-224190","volume":"82","author":"L van Esveld","year":"2023","unstructured":"van Esveld L, Cox JM, Kuijper TM et al (2023) Cost\u2013utility analysis of tapering strategies of biologicals in rheumatoid arthritis patients in the Netherlands. Ann Rheum Dis 82(10):1296\u20131306","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"6928_CR44","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1016\/j.cgh.2021.01.006","volume":"20","author":"N Vande Casteele","year":"2022","unstructured":"Vande Casteele N, Abreu MT, Flier S et al (2022) Patients with low drug levels or antibodies to a prior anti-tumor necrosis factor are more likely to develop antibodies to a subsequent anti-tumor necrosis factor. Clin Gastroenterol Hepatol: Off Clin Pract J Am Gastroenterol Assoc 20(2):465-467 e2","journal-title":"Clin Gastroenterol Hepatol: Off Clin Pract J Am Gastroenterol Assoc"},{"issue":"10","key":"6928_CR45","doi-asserted-by":"publisher","first-page":"1429","DOI":"10.1007\/s10067-013-2336-x","volume":"32","author":"CC Mok","year":"2013","unstructured":"Mok CC, van der Kleij D, Wolbink GJ (2013) Drug levels, anti-drug antibodies, and clinical efficacy of the anti-TNF\u03b1 biologics in rheumatic diseases. Clin Rheumatol 32(10):1429\u20131435","journal-title":"Clin Rheumatol"}],"container-title":["Clinical Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-024-06928-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10067-024-06928-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-024-06928-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,15]],"date-time":"2024-04-15T02:03:20Z","timestamp":1713146600000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10067-024-06928-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3,5]]},"references-count":45,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2024,5]]}},"alternative-id":["6928"],"URL":"https:\/\/doi.org\/10.1007\/s10067-024-06928-1","relation":{},"ISSN":["0770-3198","1434-9949"],"issn-type":[{"value":"0770-3198","type":"print"},{"value":"1434-9949","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,3,5]]},"assertion":[{"value":"15 January 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 February 2024","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 February 2024","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 March 2024","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The SingHealth Centralised Institutional Review Board (CIRB) approved this study and waived the need for informed consent for this database study (CIRB 2019\/2961).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"None.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosures"}}]}}